Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD (DOCK Trial)
Palo Alto (17 mi)Overseen byLucile P Gregg, MD
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Waitlist Available
Sponsor: VA Office of Research and Development
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?Almost 15% of Americans have chronic kidney disease (CKD), with an even higher rate in Veterans due to common risk factors such as high blood pressure and diabetes. People with CKD have a high risk of cardiovascular (CV) diseases, such as heart attacks, heart failure, and strokes. Extra fluid in the body, called volume overload, may lead to CV disease in people with CKD. It is unknown if volume overload develops in the earliest stages of CKD, when treating it with common, inexpensive medicines called diuretics may improve long-term CV outcomes. This study will lay important groundwork to answer this question in Veterans with early CKD by comparing two ways to measure volume overload and studying the change in common symptoms like fatigue and short-term CV function after treatment with diuretic medicines.
Eligibility Criteria
Treatment Details
1Treatment groups
Experimental Treatment
Group I: Diuretic initiation or augmentationExperimental Treatment1 Intervention
Participants will either initiate or increase the dose of a loop or thiazide-type diuretic
Find a clinic near you
Research locations nearbySelect from list below to view details:
VA North Texas Health Care System Dallas VA Medical Center, Dallas, TXDallas, TX
Loading ...
Who is running the clinical trial?
VA Office of Research and DevelopmentLead Sponsor